汉邦科技斩获第十四届金融界“金智奖”医药生物产业优胜奖，为医药强国注入持久动能

Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on "New Starting Point, New Momentum, New Journey," gathering leaders and guests from various sectors including regulatory bodies, financial institutions, and media [1] - The 14th "Golden Wisdom Award" results were announced, with Hanbang Technology winning the "Excellence Award in the Pharmaceutical and Biological Industry" [1][4] Group 1: Award Significance - The "Golden Wisdom Award" aims to establish benchmarks for high-quality development, guiding listed companies to focus on their core businesses, innovate continuously, and fulfill social responsibilities [4] - The award evaluation covered over 8,000 companies across A-shares, Hong Kong stocks, and Chinese concept stocks, ultimately recognizing nearly 200 award-winning enterprises [4] Group 2: Hanbang Technology's Achievements - Hanbang Technology is recognized for its innovation and comprehensive strength in the pharmaceutical and biological industry, focusing on high-quality development and leading industry trends [4][5] - The company has developed a full product matrix from bioreactors to purification equipment, breaking foreign technology monopolies and filling gaps in the domestic high-end biopharmaceutical equipment sector [5] Group 3: Innovation and R&D - Hanbang Technology emphasizes "innovation-driven, clinical-oriented, and people-centered" development, continuously increasing R&D investment and forming a virtuous cycle of "R&D - transformation - industrialization" [5][6] - The company’s products are widely used in the development and large-scale production of biopharmaceuticals, helping pharmaceutical companies shorten R&D cycles and reduce production costs [5] Group 4: Future Outlook - Hanbang Technology plans to continue its commitment to innovation, increasing investment in core technology R&D, and expanding into emerging fields such as cell and gene therapy [6] - The company aims to empower innovative drug R&D and clinical transformation through collaborative efforts across the industry chain, contributing to the high-quality development of the biopharmaceutical industry under the "14th Five-Year Plan" [6]